Role of Bronchoscopy in Bronchiectasis

Bronchoscopy Clinical Trial

Official title:

Bronchiectasis Phenotypes ; Clinical , Radiological and Microbiological Assesment

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04208607
• Other study ID #: Bronchoscopy in bronchiectasis
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2019
• Est. completion date: December 2020

Study information

• Verified date: December 2019
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Role of bronchoscopy in diagnosis of bronchiectasis in to different types

Description:

Bronchiectasis is defined as abnormal chronic dilatation of one or more bronchi. Patients have a structural abnormality of the bronchial wall that predisposes them to bacterial infection likely due to impaired mucus clearance. A self-perpetuating vicious cycle of chest infections and chronic lung inflammation can lead to further damage of the bronchial wall and spread of disease to normal areas of bystander lung.(1)( Wilson et al,1997).

A search for an underlying cause, which may be amenable to a targeted intervention to prevent ongoing damage, is essential but often fruitless, and the focus of therapy rapidly turns to empiric treatments to prevent infective exacerbations and retard disease progression. (2) ( Martinez-Garcia, et al,2005 ) The British Thoracic Society bronchiectasis management guidelines provide an in-depth summary of the available literature and are an excellent tool for guiding treatment decision making. However, they do not provide guidance on which patients are most likely to benefit from specific interventions. (3) (Pasteur et al, 2010).

Disease severity in bronchiectasis is hard to define. Radiological severity grading scores exist; however, there is often a disconnect between radiological severity, symptom burden and disease progression (4) (Eshed et al, 2007).

In 2014, competing bronchiectasis severity scores were published (FACED and the Bronchiectasis Severity Index (BSI). In each of these, a combination of patient demographics, symptom scores, comorbidities, and clinical, radiological and microbiological parameters were used to construct scoring systems, which, in the case of the BSI, predicted future mortality, and in the case of FACED, extended to prediction of future exacerbation frequency, hospitalisation and quality of life. (5, 6) (Chalmers et al, 2014; Martinez-Garcia et al, 2014).

These severity scores have utility in identifying an individual's risk of disease progression to a predefined outcome and aid in subclassifying this heterogeneous group of patients in a manner that may pave the way to future mechanistic studies, which explain how these different disease phenotypes arise and inform the development of targeted therapeutics. (7) (Aliberti et al, 2007).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• patients more than 18 years

• Patients less than 70 years

• Patients with bronchiectasis

Exclusion Criteria:

• patients with bronchial asthma or chronic obstructive pulmonary disease

• patients with pneumonia

• patients with T.B

Related Conditions & MeSH terms

• Bronchiectasis
• Bronchoscopy

Intervention

Procedure:
• Bronchoscopy
Role of bronchoscopy in diagnosis of bronchiectasis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of bronchiectatic patients with pseudomonal infection	Bronchoscopy will be done to all patients and bronchoalveolar lavage will be taken	One week